AUPH vs. NXTC

Last updated Apr 2, 2026

Compare and contrast key facts about Aurinia Pharmaceuticals Inc. (AUPH) and NextCure, Inc. (NXTC).

Performance

AUPH vs. NXTC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aurinia Pharmaceuticals Inc. (AUPH) and NextCure, Inc. (NXTC). The values are adjusted to include any dividend payments, if applicable.

AUPH vs. NXTC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
AUPH Aurinia Pharmaceuticals Inc.	-3.01%	77.62%	-0.11%	108.10%	-81.11%	65.37%	-31.74%	229.43%
NXTC NextCure, Inc.	-25.79%	53.37%	-32.37%	-19.15%	-76.50%	-44.95%	-80.65%	183.07%

Fundamentals

EPS AUPH : $2.06 NXTC : -$22.97
Total Revenue (TTM) AUPH : $283.06M NXTC : $0.00
Gross Profit (TTM) AUPH : $250.39M NXTC : $0.00
EBITDA (TTM) AUPH : $109.83M NXTC : -$57.50M

Returns By Period

In the year-to-date period, AUPH achieves a -3.01% return, which is significantly higher than NXTC's -25.79% return.

AUPH

• 1D: 4.39%
• 1M: 8.87%
• YTD: -3.01%
• 6M: 35.70%
• 1Y: 92.17%
• 3Y*: 12.17%
• 5Y*: 3.32%
• 10Y*: 18.02%

NXTC

• 1D: -1.40%
• 1M: -15.89%
• YTD: -25.79%
• 6M: 85.06%
• 1Y: 100.80%
• 3Y*: -15.99%
• 5Y*: -38.63%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AUPH vs. NXTC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUPH

AUPH Risk / Return Rank: 91
AUPH Sharpe Ratio Rank: 90
AUPH Sortino Ratio Rank: 88
AUPH Omega Ratio Rank: 88
AUPH Calmar Ratio Rank: 95
AUPH Martin Ratio Rank: 92

NXTC

NXTC Risk / Return Rank: 73
NXTC Sharpe Ratio Rank: 72
NXTC Sortino Ratio Rank: 75
NXTC Omega Ratio Rank: 75
NXTC Calmar Ratio Rank: 76
NXTC Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AUPH vs. NXTC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and NextCure, Inc. (NXTC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AUPH	NXTC	Difference
Sharpe ratio Return per unit of total volatility	2.04	0.96	+1.09
Sortino ratio Return per unit of downside risk	2.66	1.91	+0.75
Omega ratio Gain probability vs. loss probability	1.38	1.26	+0.12
Calmar ratio Return relative to maximum drawdown	5.81	1.97	+3.84
Martin ratio Return relative to average drawdown	12.66	3.46	+9.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AUPH vs. NXTC - Sharpe Ratio Comparison

The current AUPH Sharpe Ratio is 2.04, which is higher than the NXTC Sharpe Ratio of 0.96. The chart below compares the historical Sharpe Ratios of AUPH and NXTC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AUPH	NXTC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.04	0.96	+1.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.05	-0.53	+0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.24	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.17	-0.29	+0.46

Correlation

The correlation between AUPH and NXTC is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AUPH vs. NXTC - Dividend Comparison

Neither AUPH nor NXTC has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AUPH vs. NXTC - Drawdown Comparison

The maximum AUPH drawdown since its inception was -87.58%, smaller than the maximum NXTC drawdown of -99.71%. Use the drawdown chart below to compare losses from any high point for AUPH and NXTC.

Drawdown Indicators

	AUPH	NXTC	Difference
Max Drawdown Largest peak-to-trough decline	-87.58%	-99.71%	+12.13%
Max Drawdown (1Y) Largest decline over 1 year	-15.91%	-42.00%	+26.09%
Max Drawdown (5Y) Largest decline over 5 years	-87.58%	-97.37%	+9.79%
Max Drawdown (10Y) Largest decline over 10 years	-87.58%	—	—
Current Drawdown Current decline from peak	-53.23%	-99.05%	+45.82%
Average Drawdown Average peak-to-trough decline	-49.17%	-86.30%	+37.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.30%	23.88%	-16.58%

Volatility

AUPH vs. NXTC - Volatility Comparison

The current volatility for Aurinia Pharmaceuticals Inc. (AUPH) is 13.51%, while NextCure, Inc. (NXTC) has a volatility of 22.87%. This indicates that AUPH experiences smaller price fluctuations and is considered to be less risky than NXTC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AUPH	NXTC	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.51%	22.87%	-9.36%
Volatility (6M) Calculated over the trailing 6-month period	26.87%	80.79%	-53.92%
Volatility (1Y) Calculated over the trailing 1-year period	45.40%	106.45%	-61.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.71%	73.66%	-4.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.42%	124.34%	-49.92%

Financials